6 results about "Hirsutism" patented technology

Treatment of hirsutism, polycystic ovary syndrome, and other related conditions. This invention relates to a novel treatment for hirsutism, wherein a combination of dinogest and ethinylestradiol is administered to the subject in need.

The present disclosure is related to a topical formulation comprising clascoterone in a mixture of aqueous and oily gel phases. The present disclosure further relates to a method of treating or preventing skin conditions such acne vulgaris, acne conglobata, acne fulminans, androgenetic alopecia, hidradenitis suppurativa (also known as acne inversa), hirsutism, cancer-therapy-induced rash, eczema, rosacea, atopic dermatitis, psoriasis, inverse psoriasis, seborrheic dermatitis, acanthosis nigricans, wound, and female pattern hair loss, comprising topically administering to a subject in need thereof an effective amount of the formulation.

The present invention relates to a topical composition useful for the treatment of hair disorders such as androgenetic alopecia, hirsutism, alopecia of the eyebrow and eyelashes, hypotrichosis.

This invention belongs to the field of biomedical technology, specifically relating to the application of a composition in the preparation of a drug for the prevention and treatment of polycystic ovary syndrome (PCOS). The composition comprises bovine spleen peptide and adenosine; the mass ratio of bovine spleen peptide to adenosine is 1:(1-2.5). Bovine spleen peptide, as a bioactive polypeptide, significantly improves insulin resistance associated with PCOS by targeting and activating the PI3K-Akt signaling pathway and promoting insulin receptor substrate phosphorylation. Adenosine, as a natural bioactive substance, significantly reduces serum luteinizing hormone and testosterone levels in rats and increases follicle-stimulating hormone levels, thereby effectively alleviating hyperandrogenism symptoms such as hirsutism and acne in PCOS. Furthermore, this composition can significantly improve polycystic pathological changes in the ovarian tissue of model rats, reduce the number of cystic dilated follicles, restore the granulosa cell layer structure, alleviate ovarian stromal hyperplasia, and promote normal follicular development.

1. Name of the product in this design: Hair Management Device (Martian). 2. Purpose of this design: This design is for hair management, primarily targeting the treatment of hirsutism. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model.

The present invention relates to novel dihydropyridine derivatives of the chemical formula (I) as modulators of nuclear receptors selected from androgen and glucocorticoid receptors, to a process for their preparation, to pharmaceutical compositions containing said compounds and to the use of said compounds for the manufacture of pharmaceutical preparations for the treatment of pathological conditions or diseases that can be improved by modulating the androgen receptor and / or the glucocorticoid receptor, selected from cancer, metastatic cancer, benign prostatic hyperplasia, polycystic ovary syndrome (PCOS), hair loss, hirsutism, acne, hypogonadism, muscle-wasting diseases, cachexia, Cushing's syndrome, weight gain induced by antipsychotic drugs, post-traumatic stress disorder and alcoholism.